tert-butyl 4-(3-hydroxypyridin-2-yl)piperazine-1-carboxylate | 1374771-65-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-(3-hydroxypyridin-2-yl)piperazine-1-carboxylate
• CAS: 1374771-65-9
• 化学式: C₁₄H₂₁N₃O₃
• 分子量: 279.339
• InChiKey: WSBLNUIHECVGCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  65.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(3-hydroxypyridin-2-yl)piperazine-1-carboxylate 在 盐酸 作用下， 以 甲醇 为溶剂， 生成 2-(Piperazin-1-yl)pyridin-3-ol
  参考文献：
  名称：

  SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF

  摘要：

  The present disclosure provides compounds of Formula I: (l) (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n,p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

  公开号：

  WO2024151833A1
• 作为产物：
  描述：

  N-Boc-哌嗪 、 2-氟-3-羟基吡啶 在 N,N-二异丙基乙胺 作用下， 以 neat (no solvent) 为溶剂， 以62.8 %的产率得到tert-butyl 4-(3-hydroxypyridin-2-yl)piperazine-1-carboxylate
  参考文献：
  名称：

  SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF

  摘要：

  The present disclosure provides compounds of Formula I: (l) (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n,p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

  公开号：

  WO2024151833A1

文献信息

• [EN] FGFR2 MODULATORS<br/>[FR] MODULATEURS DE FGFR2
  申请人：EXELIXIS INC

  公开号：WO2012061337A1

  公开（公告）日：2012-05-10

  A compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein:R3a, R2, R3b, R4b, L1, G and J are as defined in the specification, pharmaceutical compositionsthereof, and methods of use thereof.

  一个由化学式（I）组成的化合物，或其药学上可接受的盐，其中：R3a、R2、R3b、R4b、L1、G和J的定义如规范中所述，以及其药物组成物和使用方法。